Literature DB >> 20167971

Hepatitis C virus: molecular biology & current therapeutic options.

Suresh D Sharma1.   

Abstract

Hepatitis C virus (HCV) is a small (approximately 55 to 65 nm), spherical, enveloped, hepatotropic RNA virus that causes acute and chronic hepatitis in humans. Persistent virus infection with HCV often leads to cirrhosis and hepatocellular carcinoma (HCC). At present there is neither a selective antiviral therapy nor a preventive vaccine. The only available treatment option is a long-acting pegylated-interferon-alpha, given in combination with nucleoside analog ribavirin, which is not very effective. Molecular studies of HCV began with the successful cloning of its genome in 1989. For many years, research to develop therapeutics was stalled by the inability to grow virus in tissue culture. A major milestone was achieved with the recent development of a robust cell culture system for HCV propagation. HCV proteins assemble and form replication complexes on modified host membranes, called as membranous webs. Even though HCV is detected and targeted by host immune mechanisms, it establishes and maintains a life-long persistent infection. HCV has evolved multiple strategies to survive and persist in hostile cellular environments; and the viral population is known to rapidly change during the course of a natural infection thereby escaping immune surveillance. Rapid mutations also help virus to survive by selecting for the variants which are resistant to antiviral drugs. Although precise mechanisms regulating HCV entry into hepatic cells via receptors remain unknown, HCV also has the capability of direct cell-to-cell transmission. The extremely complex and incompletely understood nature of the HCV lifecycle has complicated the discovery of new therapies. A complete understanding of the functional roles played by the HCV proteins during HCV lifecycle is vital for developing a successful cure. This review deals with current status of efforts in addressing these daunting tasks and challenges in developing therapeutics against chronic and rapidly changing hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167971

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  23 in total

Review 1.  Mixing the right hepatitis C inhibitor cocktail.

Authors:  Michael A Gelman; Jeffrey S Glenn
Journal:  Trends Mol Med       Date:  2010-11-23       Impact factor: 11.951

2.  Prevalence of hepatitis C virus antibody among undergraduates in ogbomoso, southwestern Nigeria.

Authors:  Abiodun Christopher Jemilohun; Bolaji Oyetunde Oyelade; Sebastine Oseghae Oiwoh
Journal:  Afr J Infect Dis       Date:  2014

3.  Identification of novel human kinases that suppress hepatitis C virus infection.

Authors:  A Lee; S Liu; T Wang
Journal:  J Viral Hepat       Date:  2013-11-10       Impact factor: 3.728

4.  Identification of ligands that target the HCV-E2 binding site on CD81.

Authors:  Reem Al Olaby; Hassan M Azzazy; Rodney Harris; Brett Chromy; Jost Vielmetter; Rod Balhorn
Journal:  J Comput Aided Mol Des       Date:  2013-04-24       Impact factor: 3.686

5.  Hepatitis C virus (HCV) interaction with astrocytes: nonproductive infection and induction of IL-18.

Authors:  Ziqing Liu; Fang Zhao; Johnny J He
Journal:  J Neurovirol       Date:  2014-03-27       Impact factor: 2.643

Review 6.  Dendritic cell-based immunity and vaccination against hepatitis C virus infection.

Authors:  Yun Zhou; Ying Zhang; Zhiqiang Yao; Jonathan Patrick Moorman; Zhansheng Jia
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

7.  Host proteins associated with Hepatitis C virus encoded NS4A.

Authors:  Prerna Dabral; Lohit Khera; Rajeev Kaul
Journal:  Virusdisease       Date:  2014-11-12

8.  Treatment of hepatitis C infections with interferon: a historical perspective.

Authors:  Robert M Friedman; Sara Contente
Journal:  Hepat Res Treat       Date:  2010-09-06

9.  Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors.

Authors:  Ziqing Liu; Johnny J He
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

Review 10.  Post-translational modifications of hepatitis C viral proteins and their biological significance.

Authors:  Jana Hundt; Zhubing Li; Qiang Liu
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.